28 April 2017 - Welcome to the latest drug price scandal: a rare disease treatment with a list price of more than $700,000 per year.
The FDA on Thursday gave its green light to the medicine, BioMarin Pharmaceutical's Brineura. It's the first-ever drug approved for a form of Batten disease, a rare genetic disorder that ravages the nervous system and can cause symptoms ranging from seizures to trouble coordinating muscles to vision loss. It can affect both adults and children; Brineura is approved for kids who are at least three years old.